

ASTRAZENECA PLC  
Form 6-K  
March 31, 2014

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of March 2014

Commission File Number: 001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_\_

## Edgar Filing: ASTRAZENECA PLC - Form 6-K

### Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4

On 28 March 2014, Dr Briggs Morrison, EVP, Global Medicines Development & Chief Medical Officer, a person discharging managerial responsibilities, was granted awards under the terms of the AstraZeneca Investment Plan (AZIP), the AstraZeneca Performance Share Plan (AZPSP) and the AstraZeneca Deferred Bonus Plan (AZDBP) over the Company's American Depositary Shares (ADSs) as detailed below. One ADS equals one ordinary share.

Name	Shares awarded under AZIP	Shares awarded under AZPSP	Shares awarded under AZDBP	Award price per share
Briggs Morrison	4,004	24,025	2,173	\$64.68

The AZIP award is subject to a four-year performance period (1 January 2014 to 31 December 2017) and a subsequent four-year holding period (1 January 2018 to 31 December 2021).

The AZPSP award is subject to a three-year performance period (1 January 2014 to 31 December 2016).

The AZDBP award is subject to a three-year holding period (28 March 2014 to 27 March 2017).

A summary of these plans and information about the performance measures that relate to the AZIP and AZPSP awards is set out in the Directors' Remuneration Report in the AstraZeneca Annual Report and Form 20-F Information 2013 which is available on the Company's website [www.astrazeneca.com](http://www.astrazeneca.com).

A C N Kemp  
Company Secretary  
31 March 2014

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Date: 31 March 2014

By: /s/ Adrian Kemp  
Name: Adrian Kemp  
Title: Company Secretary